

REMARKS

Consideration of the application as amended above is respectfully requested.

In the specification, the new paragraph was inserted after the "TITLE OF THE INVENTION" paragraph on page 1, line 3 and before the "BACKGROUND OF INVENTION" paragraph on page 1, line 5, to provide the priority of the present application.

Claims 1 to 10 were pending in the International Phase. Claims 6 and 10 have been amended, and new Claims 11 to 13 have been added. Presently, Claims 1-13 are pending in the present application.


Claim 6 has been amended to correct the punctuation following the first claimed compound from a comma to a semicolon for consistency.

Claim 10 has been amended to refer to a "first" compound and a "second" compound, and to depend from Claim 1 with respect to the first compound. New Claims 11 to 13 depend, directly or indirectly from Claim 10 and are directed to pharmaceutical compositions. Claim 11 specifies that the first compound is one of the compounds from original Claim 6. Claim 12 depends from Claim 11 and specifies that the second compound is a DP-IV compound selected from the list of compounds on pages 27 to 30 of the specification as filed. Claim 13 depends from Claim 11 and specifies that the second compound is selected from testosterone, a testosterone precursor, a testosterone prodrug, a testosterone analog and an androgen receptor agonist. Support for this amendment is found in original Claim 10 and in the specification at page 18, line 29 to page 19, line 2.

Applicants respectfully contend that the application is allowable, and a favorable response from the Examiner is earnestly solicited.

Respectfully submitted,

By

  
Catherine D. Fitch, Reg. No. 36,502  
Attorney for Applicants

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907

September 27, 2006

Tel: (732)594-4283